Fruitflow dietary supplement group Provexis gets a boost
A look at some of the biggest London-listed risers and fallers today
Company
Avacta Group PLC
LON:AVCT
At Avacta we have developed Affimer technology, an engineered alternative to antibodies. Based on a small protein, Affimer technology can be quickly developed to bind with high specificity and affinity to a wide range of targets. Affimer proteins can be developed as therapeutic molecules and can be used in a wide range of other life sciences applications in research and diagnostics.
207 stories · page 10 of 11
Avacta awarded patent for Affirmer technology in China
The principal patent protecting the Affimer technology has been accepted
Footsie up ahead of close; unrest at ITV hits shares
The bulls could not quite push the top-share index above 7,400. Tomorrow they'll have a harder job with ex-div stocks lopping about 14 points off the Footsie
Archive
Small cap movers: PhotonStar shines out on internet-of-things platforms roll-out to student accomodation
A look back at some of the week's more interesting stories from those on the junior market
Archive
Proactive news round-up: Avacta Group, Galantas Gold, Aminex …
A glance at some of the stories on the Proactive newswire today
Motif Bio gains as Rodman & Renshaw hikes target price
A look at the top risers and fallers in London on Monday
Avacta Group says it is at "value inflection point" as customer trial results in deal
The deal validates the licensing model, says chief executive, Dr Alastair Smith
FTSE 100 closes over 2% higher as France vote cheers
The FTSE 100 closed 150 points, or 2.11% higher, as investors welcomed Macron's result in the first round of France's presidential election
Innovative Avacta building the framework for success
Avacta has developed an innovative protein-scaffold platform, with potential applications in the life sciences research, diagnostic and therapeutic markets
Finncap highlights upcoming immunogenicity data for Avacta's Affimer protein scaffold as another key "milestone“
The data, expected in the next month or so, will keep the biotech firm on track to take the first Affimer candidate into phase 1 studies, targeted for 2019
Capital Network analyst thinks biotech firm Avacta "significantly undervalued"
Riccardo Lowi said his sum-of-the-parts valuation for Avacta produces an equity value of £140mln, against a current market cap of around £50mln
FTSE 100 stocks endure a refund as supermarket Morrison falls
FTSE 100 stocks bagged a net loss on Thursday after supermarket chain WM Morrison fell on an uncertain outlook
Archive
Day ahead: Morrison's results revival expected; ECB to hold pat on policy
The FTSE 100-listed food retailer reported a 2.9% increase in its like-for-like sales, for the first nine weeks of the fourth quarter - its best performance in seven years.
Archive
Limited wiggle in the Budget for Hammond
The Chancellor of the Exchequer may have a lower debt burden to deal with than he was expecting at the time of the Autumn Statement but he is unlikely to splurge
Avacta Group expects first licensing deal in 2017
Orders in 2016 rose by 70% as more life science company customers started to evaluate the technology
City broker expecting big things from Avacta
finnCap expects the group to more than double its share price within the next year as it continues to develop its Affimer PD-L1 checkpoint inhibitors
Week Ahead: Retailers ASOS and Burberry go head-to-head
The collapse of sterling will have been a boon to both retailers
Investments and investor services
Risers & Fallers: IronRidge, MX Oil , Prospex Oil & Gas...
Below are some of the main news-driven share price changes at 4.15pm